PhaseBio to Present at Stifel 2018 Healthcare Conference

MALVERN, Pa. and SAN DIEGO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, with an initial focus on cardiopulmonary disorders, today announced that Chief Executive Officer Jonathan P. Mow will present a company overview at the Stifel 2018 Healthcare Conference on Tuesday, November 13, at 11 a.m. EST in New York, NY.

A live and archived version of the presentation will be available on the company’s website at https://investors.phasebio.com.

About PhaseBio

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary disorders. The company’s lead development candidate is PB2452, a novel reversal agent for the antiplatelet therapy ticagrelor. PhaseBio is also leveraging its proprietary elastin-like polypeptide (ELP) technology platform to develop therapies with the potential for less-frequent dosing and improved pharmacokinetics. PhaseBio’s second product candidate PB1046, which is based on ELP, is a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension (PAH).

PhaseBio is located in Malvern, PA and San Diego, CA. For more information, please visit www.phasebio.com.

Investor Contact:John SharpPhaseBio Pharmaceuticals, Inc. Chief Financial Officer(610) 981-6506[email protected]

Media Contact:Sarah Hall6 Degrees(215) 313-5638[email protected]

Source: PhaseBio Pharmaceuticals, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In